Ovarian Stimulation for In Vitro Fertilization and Long-term Risk of Breast Cancer

Alexandra W. van den Belt-Dusebout, Mandy Spaan, Cornelis B. Lambalk, Marian Kortman, Joop S. E. Laven, Evert J. P. van Santbrink, Lucette A. J. van der Westerlaken, Ben J. Cohlen, Didi D. M. Braat, Jesper M. J. Smeenk, Jolande A. Land, Mariette Goddijn, Ron J. T. van Golde, Minouche M. van Rumste, Roel Schats, Katarzyna Jozwiak, Michael Hauptmann, Matti A. Rookus, Curt W. Burger, Flora E. van Leeuwen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

38 Citations (Scopus)

Abstract

IMPORTANCE Previous studies of breast cancer risk after in vitro fertilization (IVF) treatment were inconclusive due to limited follow-up.

OBJECTIVE To assess long-term risk of breast cancer after ovarian stimulation for IVF.

DESIGN, SETTING, AND PARTICIPANTS Historical cohort (OMEGA study) with complete follow-up through December 2013 for 96% of the cohort. The cohort included 19 158 women who started IVF treatment between 1983 and 1995 (IVF group) and 5950 women starting other fertility treatments between 1980 and 1995 (non-IVF group) from all 12 IVF clinics in the Netherlands. The median age at end of follow-up was 53.8 years for the IVF group and 55.3 years for the non-IVF group.

EXPOSURES Information on ovarian stimulation for IVF, other fertility treatments, and potential confounders was collected from medical records and through mailed questionnaires.

MAIN OUTCOMES AND MEASURES Incidence of invasive and in situ breast cancers in women who underwent fertility treatments was obtained through linkage with the Netherlands Cancer Registry (1989-2013). Breast cancer risk in the IVF group was compared with risks in the general population (standardized incidence ratios [SIRs]) and the non-IVF group (hazard ratios [HRs]).

RESULTS Among 25 108 women (mean age at baseline, 32.8 years; mean number of IVF cycles, 3.6), 839 cases of invasive breast cancer and 109 cases of in situ breast cancer occurred after a median follow-up of 21.1 years. Breast cancer risk in IVF-treated women was not significantly different from that in the general population (SIR, 1.01 [95% CI, 0.93-1.09]) and from the risk in the non-IVF group (HR, 1.01 [95% CI, 0.86-1.19]). The cumulative incidences of breast cancer at age 55 were 3.0% for the IVF group and 2.9% for the non-IVF group (P = .85). The SIR did not increase with longer time since treatment (>= 20 years) in the IVF group (0.92 [95% CI, 0.73-1.15]) or in the non-IVF group (1.03 [95% CI, 0.82-1.29]). Risk was significantly lower for those who underwent 7 or more IVF cycles (HR, 0.55 [95% CI, 0.39-0.77]) vs 1 to 2 IVF cycles and after poor response to the first IVF cycle (HR, 0.77 [95% CI, 0.61-0.96] for = 4 collected oocytes).

CONCLUSIONS AND RELEVANCE Among women undergoing fertility treatment in the Netherlands between 1980 and 1995, IVF treatment compared with non-IVF treatment was not associated with increased risk of breast cancer after a median follow-up of 21 years. Breast cancer risk among IVF-treated women was also not significantly different from that in the general population. These findings are consistent with absence of a significant increase in long-term risk of breast cancer among IVF-treated women.

Original languageEnglish
Pages (from-to)300-312
Number of pages13
JournalJAMA - Journal of the American Medical Association
Volume316
Issue number3
DOIs
Publication statusPublished - 19-Jul-2016

Keywords

  • FERTILITY DRUGS
  • COLLABORATIVE REANALYSIS
  • WOMEN
  • IVF
  • COHORT
  • PREGNANCY
  • HORMONE
  • GONADOTROPIN
  • METAANALYSIS
  • EXPOSURE

Cite this